• FAISL, FAK and TNBC: What the Study Shows

  2026-10-12

  A 2024 Advanced Science study proposes that the long noncoding RNA FAISL stabilizes focal adhesion kinase (FAK) by limiting Calpain 2-mediated proteolysis, thereby supporting triple-negative breast cancer progression and metastasis. The evidence combines tumor-dataset analysis, molecular interaction studies, cancer-cell phenotypes and mouse models, but remains preclinical and does not establish a clinical treatment strategy or a role for ionomycin.

• FAISL, FAK, and TNBC: What the Study Shows

  2026-10-12

  A source-grounded overview of a 2024 Advanced Science study linking the long noncoding RNA FAISL to FAK protein stability, Calpain 2-mediated proteolysis, and aggressive triple-negative breast cancer behavior. The available evidence supports a mechanistic model in cellular and mouse models, but does not establish clinical efficacy or connect the findings to ionomycin.

• Saracatinib and Reelin–SFK Evidence Gaps

  2026-10-11

  The published mouse study supports a permissive role for Reelin–Apoer2–Src-family-kinase signaling in ketamine-associated synaptic and behavioral effects, but it does not establish Saracatinib (AZD0530) as the compound responsible or demonstrate a human antidepressant application. The main evidence gap is the distance between pathway-level pharmacology and compound-specific, clinically applicable conclusions.

• Protease Inhibition in Cancer Research: Evidence and Limits

  2026-10-10

  A source-grounded overview of the DiscoveryProbe™ Protease Inhibitor Library, its conceptual uses in protease activity modulation, and how its research relevance compares with published findings on PSMD14, CARM1, and hepatocellular carcinoma.

• Eclipta–Hordeum Extract Delays Precocious Puberty

  2026-10-09

  A 2025 rat study found that an Eclipta prostrata–Hordeum vulgare extract complex delayed vaginal opening, reduced ovarian maturation, and attenuated hypothalamic GnRH mRNA elevation in Danazol- and high-fat-diet models of precocious puberty. The work is notable for testing the same botanical intervention across pharmacological and metabolic model contexts, while remaining preclinical and hypothesis-generating.

• Canagliflozin Hemihydrate: Beyond SGLT2

  2026-10-09

  Canagliflozin hemihydrate offers translational researchers a mechanism-defined way to study renal glucose reabsorption and glucose homeostasis without overclaiming mTOR activity. This article interprets recent yeast-screening evidence, outlines an evidence framework for metabolic studies, and distinguishes product provenance from biological validation.

• MAPK10–KRT16 Axis in NSCLC Metastasis

  2026-10-08

  A 2026 study identifies MAPK10 as a metastasis-suppressing kinase that phosphorylates KRT16, enabling RNF213-mediated ubiquitination and proteasomal degradation. Cellular, animal, and clinical evidence supports the MAPK10–KRT16–RNF213 axis as a mechanistic framework, while the limited clinical cohort and need for independent validation constrain immediate translational conclusions.

• Novel PRRSV-1 in Southern China: Genome and Pathogenicity

  2026-10-08

  Xu et al. report the isolation and characterization of GD2022, a PRRSV-1 strain identified in southern China, combining cell-based recovery, molecular confirmation, genome-wide analysis, and piglet pathogenicity assessment. The study strengthens surveillance evidence for PRRSV-1 diversity in China while showing why a single isolate should not be treated as a population-wide or vaccine-performance conclusion.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-10-07

  Breen and colleagues developed a genetically drug-sensitized yeast platform that improves detection of compounds affecting the TOR pathway while distinguishing rapamycin-dependent mechanisms from broader TOR inhibition. The study identified strong sensitivity gains for benchmark inhibitors, detected an otherwise obscure AZD8055 response, and found no evidence that canagliflozin inhibited TOR in this model.

• Osteoblast ECM1 and Anti-Androgen Resistance

  2026-10-07

  Wang and colleagues identify a bone-microenvironment mechanism in which enzalutamide-treated osteoblasts increase ECM1 secretion, enabling prostate cancer cells to resist anti-androgen therapy through an ENO1–GRB2–SOS1–MAPK axis. The study shifts attention from tumor-intrinsic resistance alone toward stromal signals and supports ECM1 and ENO1 as candidate intervention points, while remaining preclinical and mechanistically bounded.

• ATP as a Translational Signal in Immunogenic Cell Death

  2026-10-06

  ATP is more than a metabolic currency in oncology research: in immunogenic cell death, extracellular ATP can function as a damage-associated signal that links tumor-cell injury to immune activation. This article interprets findings from a 2026 colorectal cancer study and explains how a Luminescent ATP Detection Assay Kit can contribute to a broader, evidence-aware translational strategy without treating ATP as a standalone surrogate for immune efficacy.

• 2'-O-Methyladenosine: Evidence and Research Context

  2026-10-06

  2'-O-Methyladenosine is a ribose-modified purine nucleoside relevant to RNA modification biology and purine metabolism studies. This overview examines what current analytical evidence supports, how the compound may be interpreted in conceptual research applications, and why catalog claims about signaling, antiviral activity, or biomarkers require independent validation.

• Cy3 NHS Ester (Non-Sulfonated) Overview

  2026-10-05

  Cy3 NHS ester (non-sulfonated) is a supplier-described fluorescent NHS-ester dye for conceptual labeling of amino-containing biomolecules. No matched paper evidence was provided, so the stated properties are product-information claims rather than independently verified performance results.

• Fructus Rubi Diterpene Glycosides in BPH

  2026-10-05

  A 2025 Journal of Ethnopharmacology study reports that diterpene glycosides from Fructus Rubi reduced androgen-associated prostate enlargement in a rat model and suppressed proliferation in DHT-exposed RWPE-1 cells. Its principal contribution is a linked mechanistic model involving androgen receptor signaling and the S100A2-mediated TGF-β/Smad axis, although the findings remain preclinical and require independent validation.

• PPARG R212W in FPLD3: Rosiglitazone Rescue

  2026-10-04

  A 2026 study links the PPARG p.Arg212Trp (R212W) variant to familial partial lipodystrophy type 3 through reduced transcriptional activity, accelerated protein degradation, mitochondrial dysfunction, and impaired adipocyte metabolic gene expression. The reported partial rescue by rosiglitazone supports a mechanistic hypothesis for ligand-responsive dysfunction, while remaining preclinical and insufficient to establish clinical treatment efficacy.

8564 records 1/571 page Next 12345 下5页 Last page